Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout

doi:10.1371/journal.pone.0234909

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24796

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24796

Title:	Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout
Authors:	Yen, FS;Hsu, CC;Li, HL;Wei, JCC;Hwu, CM
Date:	2020
Issue Date:	2022-08-09T08:08:08Z (UTC)
Publisher:	PUBLIC LIBRARY SCIENCE
ISSN:	1932-6203
Abstract:	Objectives Although studies have demonstrated the association of hyperuricemia with cardiovascular (CV) diseases, few have explored the effect of urate-lowering therapy (ULT) on the incidence of CV diseases. Therefore, we compared the risks of hospitalized coronary artery disease (CAD), stroke, heart failure (HF), and all-cause mortality between ULT users and nonusers among patients with gout. Methods We performed this retrospective cohort study using Taiwan's population-based National Health Insurance Research Database. In total, 5218 patients with gout were included from 2000 to 2012. We compared the incidence rates (IRs) of hospitalized CAD, stroke, HF, and all-cause mortality between ULT users and matched nonusers. Results The IRs of hospitalized stroke were 0.6 and 1.0 per 100 person-years for ULT users and nonusers, respectively, after adjusting for age, sex, residence, comorbidities, and medications. ULT users showed lower adjusted hazard ratios (aHR) for hospitalized stroke (aHR: 0.52,p< 0.001) and all-cause mortality (aHR: 0.6,p= 0.02) than nonusers. Subgroup analyses revealed that uricosuric agents and xanthine oxidase inhibitors were significantly associated with lower risks of hospitalized stroke and all-cause mortality, respectively. The effect of uricosuric agents on the decrease in hospitalized stroke risk indicated a dose-response relationship. Conclusions Our study showed lower risks of hospitalized stroke and all-cause mortality in ULT users than in nonusers among patients with gout. Therefore, patients with gout may receive ULT to mitigate the risks of hospitalized stroke and mortality.
URI:	http://dx.doi.org/10.1371/journal.pone.0234909 https://www.webofscience.com/wos/woscc/full-record/WOS:000544972400005 https://ir.csmu.edu.tw:8080/handle/310902500/24796
Relation:	PLOS ONE ,2020 ,v15 ,issue 6
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	140	View/Open

Loading...